Vasoactive substances in the circulatory dysfunction of cirrhosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 61, Issue 6, 2001, Pages 421-429

  Moller S ^a   Bendtsen, F ^a   Henriksen, J H ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Arterial compliance; Cirrhosis; Cirrhotic cardiomyopathy; Haemodynamic derangement; Vasoactive substances

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; ENDOTHELIN 1; NITRIC OXIDE; RENIN; SODIUM; VASOACTIVE AGENT; VASODILATOR AGENT; VASOPRESSIN; WATER;

ADRENERGIC SYSTEM; ARTERY COMPLIANCE; BLOOD VOLUME; CARDIOMYOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; EXCITATION CONTRACTION COUPLING; HEART ARREST; HEART DISEASE; HEMODYNAMIC MONITORING; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASODILATATION; WATER RETENTION;

BLOOD CIRCULATION; CALCITONIN GENE-RELATED PEPTIDE; CARDIOVASCULAR SYSTEM; ENDOTHELINS; FIBROSIS; HEART; HUMANS; NATRIURETIC AGENTS; NITRIC OXIDE; PROSTAGLANDINS; TROPONIN; VASCULAR RESISTANCE; VASOPRESSINS;

EID: 17944366961     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510152567059     Document Type: Review

References (72)

1. Pathophysiology of renal fluid retention
2. The systemic circulation in cirrhosis
3. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem
4. Arteriolar vasodilatation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis
5. Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences
6. Vasodilatation associated with hepatocellular disease: Relation to functional organ failure
7. Endothelins in chronic liver disease
8. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension
9. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis
10. The renin-angiotensin-aldosterone system in liver disease
11. The sympathetic nervous system in liver disease
12. Continuous blood pressure monitoring in cirrhosis - Relations to splanchnic and systemic haemodynamics
13. Arterial compliance in patients with cirrhosis. High stroke volume/pulse pressure ratio as an index of elevated arterial compliance
14. Is there a cirrhotic cardiomyopathy?
15. Peripheral arterial vasodilatation: Determinant of functional spectrum of cirrhosis
16. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats
17. Hyporeactivity of mesenteric resistance arteries in portal hypertensive rats
18. Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis
19. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome
20. Neurohumoral fluid regulation in chronic liver disease
21. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites
22. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites
23. Calcitonin gene-related peptide in hepatorenal syndrome
24. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis
25. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats
26. Vasodilatation and hyperdynamic circulatory state in chronic liver disease
27. Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems
28. Atrial natriuretic peptide and other natriuretic factors in cirrhosis
29. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis
30. Atrial natriuretic factor in cirrhotic patients with tense ascites. Effect of large-volume paracentesis
31. Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention
32. Urinary excretion of urodilatin in patients with cirrhosis
33. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure
34. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites
35. A prognostic model for predicting survival in cirrhosis with ascites
36. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis
37. Reduced central blood volume in cirrhosis
38. Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: Effects of posture
39. Increased arterial compliance in decompensated cirrhosis
40. High arterial compliance in cirrhosis is related to elevated circulating calcitonin gene-related peptide (CGRP) and low adrenaline, but not to activated vasoconstrictor systems
41. Analysis of impaired exercise capacity in patients with cirrhosis
42. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis
43. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis
44. Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis
45. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors
46. Cirrhotic cardiomyopathy: Getting to the heart of the matter
47. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites
48. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt
49. Cirrhotic cardiomyopathy and liver transplantation
50. Elevated circulating cardiac troponin I in patients with cirrhosis
51. Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis
52. Cardiac excitation-contraction coupling in the portal hypertensive rat
53. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes
54. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis
55. Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy
56. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats
57. Differential responses of plasma atrial and brain natriuretic peptides to acute alteration in atrial pressure in pigs
58. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis
59. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis
60. Hepatorenal disorders. Role of the renin-angiotensin-aldosterone system
61. Estimated central blood volume in cirrhosis - Relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor
62. Evaluation of brain natriuretic peptide in the diagnosis of heart failure
63. BNP: Soon to become a routine measure in the care of patients with heart failure?
64. Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) concentrations
65. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma
66. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction
67. An immunoluminometric assay for N-terminal probrain natriuretic peptide: Development of a test for left ventricular dysfunction
68. Hepatic-intestinal disposal of endogenous human alpha natriuretic factor in patients with cirrhosis
69. Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure
70. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase
71. Vasopeptidase inhibition: A new concept in blood pressure management
72. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides